Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Glostrup University Hospital, Copenhagen | OTHER |
| Rigshospitalet, Denmark | OTHER |
| Institute of Psychiatry, London | OTHER |
| UMC Utrecht |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology. Additionally, the investigators want to examine the influence of D2 receptor blockade on these disturbances. The investigators expect disturbances in the dopaminergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and investigators expect D2 receptor blockade to reverse some of the functional and cognitive impairments.
The study is designed as a 6 week case-control follow-up study of 70 AN FE pt. with SCZ and 70 controls matched with regard to age, gender, and parental socio-economic status. All subjects will be examined with a diagnostic interview (SCAN, Schedule for Clinical Assessment in Neuropsychiatry), medical and family history, and physical examination before inclusion. At baseline all subjects will be examined with single photon emission computed tomography (SPECT), MRI, fMRI, psychophysiology, neurocognition. In addition, they will be screened for drugs, genetic testing, and ECG. Patients will further be examined with clinical validated rating scales to measure psychopathology, subjective well-being, and side-effects. After a period of 6 weeks all assessments are repeated. During that period patients will be treated with amisulpride, while healthy controls will receive no treatment at all. Efficacy of antipsychotic treatment will be evaluated after this initial period of 6 weeks. Based on this evaluation it will be decided to either continue the current (amisulpride) antipsychotic treatment, or to switch to aripiprazole. Efficacy of aripiprazole is evaluated on a monthly basis, if the patient does not respond well enough, than the treatment will be adapted individually. Regardless of treatment, all subjects will be re-assessed in the same test battery as mentioned above, except for SPECT and fMRI, after a period of 6, 12, and 24 months. The developement in specific disturbances and the relationship between these will be analysed.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| first choice treatment | Active Comparator | Treatment with amisulpride |
|
| second choice treatment | Active Comparator | treatment with aripiprazole |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| amisulpride | Drug | Individually dosed, according to symptoms, for a period of 6 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Relationship between specific neuropsychiatric measures and improvement on PANSS scores | 6 weeks of medical treatment |
| Measure | Description | Time Frame |
|---|---|---|
| The relation between D2 binding potential (SPECT) and reward related brain activity (fMRI BOLD response) before and after D2 blockade | Baseline, 6 weeks | |
| Time/dose improvement on PPI and other psychophysiological measures of early information processing after D2 blockade |
Not provided
Inclusion Criteria:
For patients: meeting diagnostic criteria for schizophrenia according to ICD 10 or DSM IV antipsychotic naive The controls will be matched to the patients according to gender age and parental socio-economic status.
-
Exclusion Criteria:
Patients: mental retardation, other chronic diseases, use of antidepressive medicine during the last month,being pregnant, on going substance abuse
Controls: psychiatric diagnosis, psychiatric diagnosis in first-degree relatives,on going drug abuse, mental retardation -
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Birte Y Glenthoj, professor | University of Copenhagen, Psychiatric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup | Glostrup Municipality | DK-2600 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33933719 | Derived | Thomas MB, Raghava JM, Pantelis C, Rostrup E, Nielsen MO, Jensen MH, Glenthoj BY, Mandl RCW, Ebdrup BH, Fagerlund B. Associations between cognition and white matter microstructure in first-episode antipsychotic-naive patients with schizophrenia and healthy controls: A multivariate pattern analysis. Cortex. 2021 Jun;139:282-297. doi: 10.1016/j.cortex.2021.03.003. Epub 2021 Mar 18. | |
| 30642415 |
| Label | URL |
|---|---|
| homepage of the research unit | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077582 | Amisulpride |
| D000068180 | Aripiprazole |
| ID | Term |
|---|---|
| D001549 | Benzamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D001565 | Benzoates |
| D000146 |
Not provided
Not provided
| OTHER |
| Copenhagen Hospital Corporation | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| aripiprazole | Drug | Individually dosed, according to symptoms, for a period of 6 weeks |
|
|
| Baseline, 2 and 6 weeks, 6,12,24 months |
| Disturbances in reward related fMRI BOLD response in antipsychotic naive schizophrenic patients | Baseline and 6 weeks follow up |
| Structural changes in grey and white matter before and after D2 blockade | 6 weeks, 6, 12 and 24 months, |
| Cognitive differences at baseline and changes over time after D2 blockade | Baseline, 6 weeks, 6,12,24 months |
| The effect of D2 blockade on reward related fMRI BOLD response | 6 weeks of medical treatment |
| Derived |
| Wulff S, Nielsen MO, Rostrup E, Svarer C, Jensen LT, Pinborg L, Glenthoj BY. The relation between dopamine D2 receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients. Psychol Med. 2020 Jan;50(2):220-228. doi: 10.1017/S0033291718004099. Epub 2019 Jan 15. |
| 30560750 | Derived | Ebdrup BH, Axelsen MC, Bak N, Fagerlund B, Oranje B, Raghava JM, Nielsen MO, Rostrup E, Hansen LK, Glenthoj BY. Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naive schizophrenia patients. Psychol Med. 2019 Dec;49(16):2754-2763. doi: 10.1017/S0033291718003781. Epub 2018 Dec 18. |
| 30420252 | Derived | Jessen K, Mandl RCW, Fagerlund B, Bojesen KB, Raghava JM, Obaid HG, Jensen MB, Johansen LB, Nielsen MO, Pantelis C, Rostrup E, Glenthoj BY, Ebdrup BH. Patterns of Cortical Structures and Cognition in Antipsychotic-Naive Patients With First-Episode Schizophrenia: A Partial Least Squares Correlation Analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 May;4(5):444-453. doi: 10.1016/j.bpsc.2018.09.006. Epub 2018 Sep 25. |
| 29734953 | Derived | Jessen K, Rostrup E, Mandl RCW, Nielsen MO, Bak N, Fagerlund B, Glenthoj BY, Ebdrup BH. Cortical structures and their clinical correlates in antipsychotic-naive schizophrenia patients before and after 6 weeks of dopamine D2/3 receptor antagonist treatment. Psychol Med. 2019 Apr;49(5):754-763. doi: 10.1017/S0033291718001198. Epub 2018 May 8. |
| 29373756 | Derived | Anhoj S, Odegaard Nielsen M, Jensen MH, Ford K, Fagerlund B, Williamson P, Glenthoj B, Rostrup E. Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naive First-Episode Schizophrenia. Schizophr Bull. 2018 Oct 17;44(6):1332-1340. doi: 10.1093/schbul/sbx171. |
| 22868877 | Derived | Nielsen MO, Rostrup E, Wulff S, Bak N, Broberg BV, Lublin H, Kapur S, Glenthoj B. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry. 2012 Dec;69(12):1195-204. doi: 10.1001/archgenpsychiatry.2012.847. |
| homepage of the research unit | View source |
| Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D010879 | Piperazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D015363 | Quinolones |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |